NCT01425203View on ClinicalTrials.gov

The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)

PHASE3CompletedINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

November 23, 2011

Primary Completion Date

October 21, 2013

Study Completion Date

October 21, 2013

Conditions
Chronic Hepatitis C Genotype 1
Interventions
DRUG

Boceprevir

boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)

DRUG

Placebo

boceprevir-matched placebo four 200-mg capsules PO TID.

BIOLOGICAL

peginterferon alfa-2b

peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)

DRUG

Ribavirin

ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01425203 - The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) | Biotech Hunter | Biotech Hunter